Drug recall · July 14, 2021
Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg recall
Why: Subpotent drug: Out of specification for assay of naloxone and buprenorphine (low)
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Buprenorphine and Naloxone Sublingual Film 2mg/0.5mg, 30 pouches each containing 1 sublingual film, Distributed by: Alvogen, Inc. Pine Brook, NJ 07058 USA, NDC 47781-355-03
- Lots / codes
Lot #: 36924, Exp 6/2021
- Quantity
- 9,696 cartons
- Company
- Alvogen, Inc, Morristown, NJ
- Distribution
- USA nationwide.
- Initiated
- February 26, 2021 · Voluntary: Firm initiated
- Classified
- July 2, 2021
- Reported
- July 14, 2021
- Ended
- February 16, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Buprenorphine / naloxone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.